The information in this article is based on a press release statement from Senti Biosciences, Inc. The company's stock has experienced significant volatility, with a year-to-date decline of 67%. InvestingPro subscribers have access to additional insights, including 8 more key tips about SNTI's financial position and growth prospects. Discover comprehensive analysis and real-time updates by exploring InvestingPro's advanced features. The company's stock has experienced significant volatility, with a year-to-date decline of 67%. InvestingPro subscribers have access to additional insights, including 8 more key tips about SNTI's financial position and growth prospects. Discover comprehensive analysis and real-time updates by exploring InvestingPro's advanced features.
Schulz's career spans over 35 years at Ernst & Young (EY), where she was instrumental in the firm's expansion and served as a founding member of its Life Sciences Practice. Her expertise includes a wide array of corporate transactions, having been involved in over 100 equity and debt financings, totaling in excess of $15 billion.
In addition to her appointment to the Board, Schulz will chair the Board's Audit Committee. This announcement coincides with the departure of Dr. Omid Farokhzad from the Board, whom the company has thanked for his service.
CEO and Co-Founder of Senti Bio, Timothy Lu, MD, PhD, highlighted Schulz's alignment with the company's vision and her potential impact on their leadership in cell and gene therapy innovation. Schulz herself expressed eagerness to contribute to Senti Bio's mission, particularly their commitment to Gene Circuit technologies.
Senti Bio is leveraging its proprietary Gene Circuit platform to create therapies aimed at diseases currently considered incurable. The company's pipeline includes off-the-shelf CAR-NK cells targeting both liquid and solid tumors, and it has demonstrated the application of Gene Circuits in T cells and other modalities through partnerships with industry leaders.
The information in this article is based on a press release statement from Senti Biosciences, Inc.
In other recent news, Senti Biosciences, a biotech firm, has been flagged by Nasdaq for non-compliance with audit committee requirements. The company received a notice from Nasdaq due to having only two members in its audit committee, a shortfall from the required three members, following the resignation of Susan Berland from the Board.
This non-compliance was disclosed in an 8-K filing with the U.S. Securities and Exchange Commission. To regain compliance, Senti Biosciences has been granted a cure period, which is either until the company's next annual stockholders' meeting or June 11, 2025, whichever comes first.
The company has stated its intention to fill the vacancy on the audit committee within the given timeframe. This development follows a previous disclosure in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. However, the company's plans to address the non-compliance issue are subject to risks and uncertainties that could affect business and financial results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.